www.fdanews.com/articles/74053-anadys-announces-expiration-of-hart-scott-rodino
ANADYS ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO
July 7, 2005
Anadys Pharmaceuticals, a biopharmaceutical company committed to the discovery, development and commercialization of novel anti-infective medicines, announced today the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act for the Company's exclusive global license and co-development agreement with Novartis. In conjunction with the HSR clearance, Anadys will receive the initial license payment of $20 million from Novartis.
PharmaLive (http://www.medadnews.com/News/Index.cfm?articleid=254243)